Immuron Limited balance sheet IMRN

Annual Quarterly

Cash and investments were $2.7 million.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2024
Jun 30, 2024
Assets
Cash
3
Cash and investments
3
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
IMRN (Nasdaq)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Carlton, Victoria, Australia
SEC filer status
Non-accelerated filer
SEC CIK
1660046

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.